

## Chimeric receives \$1.8 M advance on FY26 R&D tax incentive

**Melbourne, Australia, 2 March 2026:** Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, is pleased to announce it has received \$1,785,000 from Radium Capital under a funding facility secured against Chimeric's anticipated FY26 Research and Development Tax Incentive (RDTI).

The funds will support the clinical trial pipeline and otherwise for general working capital of the Company.

The funding agreement with Radium Capital provides Chimeric with early access to a portion of the Company's anticipated FY26 RDTI. The facility is secured against the anticipated FY26 RDTI to be received from the Australian Taxation Office, with interest charged at a commercial rate. Repayment is timed to follow the anticipated receipt of the Company's FY26 RDTI, due by 31 December 2026. The facility can be repaid at any time without penalty prior to this date, subject to a minimum interest period of 90 days.

The Australian Government RDTI program provides companies engaging in eligible activities with a refundable tax offset of up to 43.5%.

### ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.

Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialisation of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

For personal use only



CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

This announcement has been authorised for release to ASX by the Chief Executive Officer.

**Contact**

Investors

Dr Rebecca McQualter  
Chief Executive Officer  
Chimeric Therapeutics  
E: [investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)  
W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Media

Matthew Wright  
NWR Communications  
T: +61 451 896 420  
E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

For personal use only